CN101491513A - New use of Radix Salviae Miltiorrhizae in treating wean pneumonia - Google Patents
New use of Radix Salviae Miltiorrhizae in treating wean pneumonia Download PDFInfo
- Publication number
- CN101491513A CN101491513A CNA2008100565529A CN200810056552A CN101491513A CN 101491513 A CN101491513 A CN 101491513A CN A2008100565529 A CNA2008100565529 A CN A2008100565529A CN 200810056552 A CN200810056552 A CN 200810056552A CN 101491513 A CN101491513 A CN 101491513A
- Authority
- CN
- China
- Prior art keywords
- danshensu
- new purposes
- pneumonia
- processed
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to novel clinical application of salvianic acid A, in particular to novel application of the salvianic acid A in treating infantile pneumonia and a preparation for the application. The salvianic acid A is an effective constituent obtained by the separation of a water extraction liquid of dry roots of Salvia miltiorrhiza, salvia, Labiatae, namely D(+)beta-(3, 4-diHydroxyphenyl)lactic acid. The salvianic acid A which is taken as a main water-soluble component in the Salvia miltiorrhiza has the characteristics of remarkable therapeutic effect, quick action, small side effect, and the like, to the treatment of severe infant pneumonia. The salvianic acid A with the novel application can be processed into a plurality of preparations such as a tablet, a capsule, a granule, an oral disintegrant, an oral liquid, an injection, and the like.
Description
Technical field:
The present invention relates to water soluble ingredient in the Radix Salviae Miltiorrhizae---the novel clinical use of danshensu specifically, relates to the new medical use that danshensu is used for the treatment of pneumonia, especially infantile pneumonia, is more preferably the severe pneumonia of infants disease.
Background technology:
Radix Salviae Miltiorrhizae is the dry root and rhizome of Labiatae salvia Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bunge, is the more deep a kind of Chinese herbal medicine of chemical constitution study.The tradition Chinese medicine thinks that Radix Salviae Miltiorrhizae has effects such as blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, clearing away heat and cooling blood.People study the chemical constituent of Radix Salviae Miltiorrhizae since the thirties in 20th century, nearly 50 kinds of the constituent of having illustrated.Studies show that liposoluble constituent mainly is the diterpene-kind compound of TANSHINONES type in the Radix Salviae Miltiorrhizae; Water soluble ingredient mainly is danshensu and protocatechualdehyde.Danshensu is isolated a kind of phenol aromatic acid compounds from Radix Salviae Miltiorrhizae in 1980, has another name called D (+) β-(3, the 4-dihydroxy phenyl) lactic acid.
The danshensu structural formula is as follows:
Physical behavior is: the crystallization of white minute hand shape, molecular formula are C
9H
10O
5, fusing point is 84 ℃～86 ℃, and its sodium salt is a white, needle-shaped crystals, and fusing point is 225 ℃～258 ℃.In ethanol, can not survey optical rotation, FeCl
3Reaction is yellow green.Infrared spectrum (KCl, cm
-1) demonstration-COOH (1732,2750～2550) and-existence of OH (3450～3150).
Development along with modernized pharmaceutical technology, people deepen continuously to the danshensu Its Mechanisms, its clinical practice is also increasingly extensive, studies show that: danshensu has antioxidation, anticoagulant, antithrombotic, resisting cardiovascular ischemia and accent blood fat, antiinflammatory, increases the preceding multiple pharmacologically active of immunity.Be mainly used in clinically invigorate blood circulation, anticoagulant and blood fat reducing.
Summary of the invention:
Main purpose of the present invention provides a kind of novel medical use of danshensu, and the danshensu preparation that relates to this new purposes.
The invention provides the new purposes of a kind of danshensu, it is characterized in that: be used to prepare medicine with prevention or treatment pneumonia.
Above-mentioned described purposes, wherein, described pneumonia preferably infantile pneumonia, be more preferably severe pneumonia of infants.
Wherein, the new purposes of above-mentioned described danshensu, wherein said medicine can be common dosage forms, for example is tablet, capsule, granule, Orally-disintegrating tablet, oral liquid or injection.
Wherein, the new purposes of above-mentioned described danshensu, tablet or the capsule be processed into proper auxiliary materials of danshensu wherein, wherein said adjuvant are selected from sucrose, lactose, starch, dextrin, mannitol, microcrystalline Cellulose, hydroxypropyl emthylcellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, polyvidone, the magnesium stearate one or more to be mixed and uses.
Wherein, the new purposes of above-mentioned described danshensu, the granule be processed into proper auxiliary materials of danshensu wherein, wherein said adjuvant are selected from sucrose, lactose, dextrin, mannitol, stevioside, aspartame, the saccharin sodium one or more to be mixed and uses.
Wherein, the new purposes of above-mentioned described danshensu, the oral liquid be processed into proper auxiliary materials of danshensu wherein, wherein said adjuvant are selected from diluent, nutrient, correctives, the antiseptic one or more to be mixed and uses.
Wherein, the new purposes of above-mentioned described danshensu, the Orally-disintegrating tablet be processed into proper auxiliary materials of danshensu wherein, wherein said adjuvant are selected from sucrose, lactose, mannitol, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, polyvidone, sodium bicarbonate, citric acid, stevioside, aspartame, the saccharin sodium one or more to be mixed and uses.
Wherein, the new purposes of above-mentioned described danshensu, the wherein injection be processed into proper auxiliary materials of danshensu.
Wherein, the new purposes of above-mentioned described danshensu, wherein said injection is liquid drugs injection, transfusion or injectable powder, described adjuvant is selected from one or more mixing uses in pharmaceutical carrier diluent, isotonic agent, the buffer agent
By the Guinea pig lung tremulous pulse that will exsomatize, use 0.95N
2+ 0.05CO
2Replace 0.95O
2+ 0.05CO
2To bring out development of hypoxic pulmonary vasoconstriction (HPV).Result of the test shows that danshensu concentration all can suppress HPV when 1.25～5gL-1.And dosage is big more, and inhibitory action is strong more, reaches at last fully to suppress.The presentation of results danshensu can be pneumonia, and especially the treatment of critical illness such as infantile pneumonia, particularly severe pneumonia of infants is offered help.
The specific embodiment
Further specify the present invention by the following examples, but do not limit the present invention.
Embodiment 1, injection
Prescription (1000ml)
Danshensu 12g
Water for injection is an amount of
Make 1000ml
Method for making: get danshensu, add in the water of recipe quantity 80%, make its whole dissolvings.Regulate pH value to 6.0～7.0 with sodium hydroxide solution, benefit adds to the full amount of water for injection; After mensuration content is qualified, behind the microporous filter membrane fine straining, press per ampoule 2ml or 5ml packing, saturated vapor was sterilized 30 minutes down at 115 ℃, cooled off laggard portable lighter inspection, and pack qualified back, promptly.
Embodiment 2, powder pin
Prescription (1000ml)
Danshensu 15g
Mannitol 150g
Water for injection 1000ml
Make 500
Method for making: get mannitol, add in the water of recipe quantity 80%, all after the dissolving, add the danshensu of recipe quantity, stirring makes dissolving fully, and benefit adds to the full amount of water for injection; After mensuration content is qualified, through the microporous filter membrane fine straining, by every 2ml packing, lyophilization, promptly.
Embodiment 3, tablet
Prescription (100,000)
Danshensu 1500g
Starch 18000g
8% starch slurry is an amount of
Magnesium stearate 200g
Make 100,000
Method for making: get danshensu and starch, with the equivalent method mix homogeneously that progressively increases, granulate with 8% starch slurry, drying is sneaked into magnesium stearate, tabletting, or bag film-coat, promptly.
Embodiment 4, granule
Prescription (100,000 bags)
Danshensu 1kg
Lactose 40kg
Cane sugar powder 160kg
Make 100,000 bags
Method for making: get cane sugar powder and lactose respectively, cross 100 mesh sieves, standby; Get danshensu and lactose,, add cane sugar powder again with the equivalent method mix homogeneously that progressively increases, mix homogeneously, the water wet granulation, drying, pack, promptly.
Embodiment 5, oral cavity disintegration tablet
Specification is every and contains danshensu (C9H10O5) 0.2mg～100mg.
Prescription (100,000)
Danshensu 1000g
Lactose 10000g
Mannitol 10000g
Microcrystalline Cellulose 2500g
Low-substituted hydroxypropyl cellulose 500g
Polyvinylpolypyrrolidone 1000g
Make 100,000
Method for making: get danshensu, lactose, mannitol, low-substituted hydroxypropyl cellulose, the polyvinylpolypyrrolidone of recipe quantity, with the equivalent method mix homogeneously that progressively increases, again with the microcrystalline Cellulose mix homogeneously, direct compression, promptly.
Embodiment 6: the Radix Salviae Miltiorrhizae in treating wean pneumonia clinical efficacy
Danshensu injection (embodiment 1) treatment infantile pneumonia clinical efficacy.And in contrast with Santanning syrup.Children with bronchial pneumonia 160 examples are divided into treatment group and matched group at random.Wherein 90 examples are organized in treatment, boy baby's infant 53 examples, girl baby's infant 37 examples, age reckling 1 month, maximum 10 years old, course of disease person below 7 days 62 examples, 7 days to 14 days person's 28 examples of the course of disease.Matched group 70 examples, boy baby's infant 36 examples, girl baby's infant 34 examples, age reckling 1 month, maximum 10 years old, course of disease person below 7 days 52 examples, 7 days to 14 days person's 18 examples of the course of disease.
Curative effect is judged: recovery from illness: treated 3 days, infant is brought down a fever, and cough ends, and pulmonary rale disappears, and check chest x-ray prompting inflammation absorbs; Produce effects: treated 7 days, infant is brought down a fever, and cough ends, and pulmonary rale disappears, and check chest x-ray prompting inflammation takes a turn for the better; Effectively: treat after 7 days, infant is brought down a fever, and cough alleviates, and pulmonary rale reduces; Invalid: above-mentioned symptom is not seen improvement, or deterioration person is arranged.
The results are shown in Table 1.
Table 1: Radix Salviae Miltiorrhizae in treating wean pneumonia clinical efficacy
Test group and matched group be P＜0.01 relatively, P
*＜0.01, P
△＜0.01, P
Zero＜0.01.
Danshensu injection for treating infantile pneumonia clinical efficacy result of the test shows that danshensu has the effect of good treatment pneumonia, is the especially good medicine of severe pneumonia of infants of infantile pneumonia, and belongs to Chinese medicine preparation, and toxic and side effects is little, drug safety.
The present invention is described according to preferred embodiment.Should be understood that the description of front and embodiment are just to illustrating the present invention.Under prerequisite without departing from the spirit and scope of the present invention, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.
Claims (8)
1. the new purposes of danshensu is characterized in that: be used to prepare the medicine that has prevention or treatment pneumonia, especially infantile pneumonia, is more preferably the severe pneumonia of infants disease.
2. the new purposes of danshensu according to claim 1, wherein said medicine is tablet, capsule, granule, Orally-disintegrating tablet, oral liquid or injection.
3. the new purposes of danshensu according to claim 2, it is characterized in that: tablet or capsule that danshensu is processed into proper auxiliary materials, wherein said adjuvant are selected from one or more mixing uses in sucrose, lactose, starch, dextrin, mannitol, microcrystalline Cellulose, hydroxypropyl emthylcellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, polyvidone, the magnesium stearate.
4. the new purposes of danshensu according to claim 2, it is characterized in that: the granule that danshensu is processed into proper auxiliary materials, wherein said adjuvant are selected from one or more mixing uses in sucrose, lactose, dextrin, mannitol, stevioside, aspartame, the saccharin sodium.
5. the new purposes of danshensu according to claim 2 is characterized in that: the oral liquid that danshensu is processed into proper auxiliary materials, wherein said adjuvant are selected from diluent, nutrient, correctives, the antiseptic one or more to be mixed and uses.
6. the new purposes of danshensu according to claim 2, it is characterized in that: the Orally-disintegrating tablet that danshensu is processed into proper auxiliary materials, wherein said adjuvant are selected from one or more mixing uses in sucrose, lactose, mannitol, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, polyvidone, sodium bicarbonate, citric acid, stevioside, aspartame, the saccharin sodium.
7. the new purposes of danshensu according to claim 2 is characterized in that: the injection that danshensu is processed into proper auxiliary materials.
8. the new purposes of danshensu according to claim 10, wherein said injection is liquid drugs injection, transfusion or injectable powder, described adjuvant is selected from pharmaceutical carrier diluent, isotonic agent, the buffer agent one or more to be mixed and uses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100565529A CN101491513A (en) | 2008-01-22 | 2008-01-22 | New use of Radix Salviae Miltiorrhizae in treating wean pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100565529A CN101491513A (en) | 2008-01-22 | 2008-01-22 | New use of Radix Salviae Miltiorrhizae in treating wean pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101491513A true CN101491513A (en) | 2009-07-29 |
Family
ID=40922417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100565529A Pending CN101491513A (en) | 2008-01-22 | 2008-01-22 | New use of Radix Salviae Miltiorrhizae in treating wean pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101491513A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107998117A (en) * | 2017-12-16 | 2018-05-08 | 姚蕾 | A kind of combination of oral medication for treating capillary leak syndrome |
-
2008
- 2008-01-22 CN CNA2008100565529A patent/CN101491513A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107998117A (en) * | 2017-12-16 | 2018-05-08 | 姚蕾 | A kind of combination of oral medication for treating capillary leak syndrome |
| CN107998117B (en) * | 2017-12-16 | 2018-09-18 | 姚蕾 | A kind of combination of oral medication for treating capillary leak syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102225138B (en) | Traditional Chinese medicine composition for treating fracture and preparation method and application thereof | |
| CN1306951C (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN103301244B (en) | Traditional Chinese medicinal preparation for treating infantile pneumonia and preparation method of traditional Chinese medicinal preparation | |
| CN101491513A (en) | New use of Radix Salviae Miltiorrhizae in treating wean pneumonia | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN101199765B (en) | Medicament for treating stomach disease | |
| CN104548033A (en) | Copperleaf-herb traditional Chinese medicine preparation for treatment of enteritis and preparation method thereof | |
| CN105232991B (en) | A kind of pharmaceutical composition for treating mucosal lesion | |
| CN105012642B (en) | A kind of promoting blood circulation and removing blood stasis, preparation method of the Chinese medicine composition of hemostasis and pain-relieving | |
| CN108743757A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating insomnia | |
| CN103349732A (en) | Dendrobium officinale kimura et migo-panax quinquefolius buccal tablets for diabetes patients, and preparation method thereof | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN108553584B (en) | Composition for assisting in reducing blood sugar and application thereof | |
| CN1220508C (en) | Medicine for curing diseases of digestive system and its preparation method | |
| CN105596655A (en) | Traditional Chinese medicine electuary for treating infantile pneumonia and preparation method of traditional Chinese medicine electuary | |
| CN101450157A (en) | Medicine composition for treating chronic bronchitis and asthma | |
| CN106236971A (en) | A kind of Chinese medicine composition treating chronic nephritis | |
| CN103893346B (en) | One treats ARR Chinese medicine of motive asthenia type and preparation method thereof | |
| CN105031364A (en) | Preparation for preventing and treating toothache due to wind-fire evil and preparation method of preparation | |
| CN106138795A (en) | Chinese medicine composition for the treatment of premature beat and preparation method thereof | |
| CN105169014A (en) | Composition for treating vasculitis and preparation method | |
| CN105250417A (en) | Pharmaceutical composition for treating diarrheic type irritable bowel syndrome and application thereof | |
| CN105125985A (en) | Chinese and western medicine compound preparation for treating senile chronic bronchitis and preparation method thereof | |
| CN114984179A (en) | Composition for treating or preventing mitiglinide adverse reaction and preparation method and application thereof | |
| CN104367896A (en) | Pharmaceutical composition for treating qi deficiency and blood stasis-type apoplexy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090729 |